Literature DB >> 19132880

Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center.

Adi Cohen1, Jessica Fleischer, Matthew J Freeby, Donald J McMahon, Dinaz Irani, Elizabeth Shane.   

Abstract

AIMS: Osteoporosis is uncommon in premenopausal women, and most cases have a secondary cause. Women with osteoporosis and no known secondary cause are said to have idiopathic osteoporosis (IOP). We aimed to estimate the proportion of premenopausal women seen in our referral center with IOP as opposed to secondary osteoporosis, to describe their clinical characteristics, to compare women with a low-trauma fracture history with those with low bone mineral density (BMD) alone, and to estimate the frequency of bisphosphonate use.
METHODS: We reviewed medical records from all premenopausal women evaluated for osteoporosis or low BMD in our center during 2005. We included premenopausal women diagnosed on the basis of low-trauma fracture, low BMD or both (Z score < or= -2.0 or T score < or = -2.5), or both.
RESULTS: Among these patients (n = 61; mean age 37 +/- 8), 57 (93%) were Caucasian, 34 (57%) had a family history of osteoporosis, and 26 (43%) had used bisphosphonates. The most common secondary causes were amenorrhea (34%, n = 21), anorexia nervosa (16%, n = 10), and glucocorticoid exposure (13%, n = 8). After exclusion of secondary causes, 39% (24 of 61) of the entire group and 48% (14 of 29) of the fracture group were thought to have IOP. Women with a known secondary cause had lower BMD Z scores at the spine and hip than those with IOP. Women with low BMD and no fractures had shorter stature and weighed less than those with fractures, but overall differences between the groups were not statistically significant. Bisphosphonates had been prescribed for 38% (11 of 29) of women with a fracture history and 47% (15 of 32) of women with low BMD and no fractures.
CONCLUSIONS: Our findings suggest that IOP is common among premenopausal women with osteoporosis or low BMD evaluated at a referral center. The smaller stature of women diagnosed only on the basis of BMD criteria raises the question of whether their areal BMD measurements are spuriously low because of smaller bone size. The high proportion of premenopausal women who had been prescribed oral bisphosphonates for low BMD measurements is of concern, as such women are likely to be at low short-term risk of fracture, and a more conservative approach to therapy is preferable in this group.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132880      PMCID: PMC3030453          DOI: 10.1089/jwh.2008.0887

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  26 in total

Review 1.  Clinical review 137: Sexual dimorphism in skeletal size, density, and strength.

Authors:  E Seeman
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

2.  Fractures before menopause: a red flag for physicians.

Authors:  W D Hosmer; H K Genant; W S Browner
Journal:  Osteoporos Int       Date:  2002       Impact factor: 4.507

3.  Perimenopausal wrist fracture--an opportunity for prevention and management of osteoporosis.

Authors:  A D Rothberg; P K Matshidze
Journal:  S Afr Med J       Date:  2000-11

4.  Fractures between the ages of 20 and 50 years increase women's risk of subsequent fractures.

Authors:  Fiona Wu; Barbara Mason; Anne Horne; Ruth Ames; Judith Clearwater; Michael Liu; Margaret C Evans; Gregory D Gamble; Ian R Reid
Journal:  Arch Intern Med       Date:  2002-01-14

5.  Pharmacovigilance study of alendronate in England.

Authors:  Pipasha N Biswas; Lynda V Wilton; Saad A W Shakir
Journal:  Osteoporos Int       Date:  2003-04-23       Impact factor: 4.507

6.  Peripheral bone mineral density in patients with distal radial fractures.

Authors:  C A Wigderowitz; T Cunningham; D I Rowley; P A Mole; C R Paterson
Journal:  J Bone Joint Surg Br       Date:  2003-04

Review 7.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

8.  Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women.

Authors:  Pilar Peris; Núria Guañabens; Ma Jesús Martínez de Osaba; Ana Monegal; Luisa Alvarez; Francesca Pons; Inmaculada Ros; Dacia Cerdá; José Muñoz-Gómez
Journal:  Semin Arthritis Rheum       Date:  2002-08       Impact factor: 5.532

9.  Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis.

Authors:  Pilar Peris; Ana Monegal; M Angeles Martínez; Concepción Moll; Françesca Pons; Nuria Guañabens
Journal:  Clin Rheumatol       Date:  2006-08-29       Impact factor: 3.650

Review 10.  Bone densitometry in premenopausal women: synthesis and review.

Authors:  Aliya A Khan; Zeba Syed
Journal:  J Clin Densitom       Date:  2004       Impact factor: 2.963

View more
  15 in total

1.  The utility of BMD Z-score diagnostic thresholds for secondary causes of osteoporosis.

Authors:  F E McKiernan; R L Berg; J G Linneman
Journal:  Osteoporos Int       Date:  2010-06-09       Impact factor: 4.507

2.  Increased marrow adiposity in premenopausal women with idiopathic osteoporosis.

Authors:  Adi Cohen; David W Dempster; Emily M Stein; Thomas L Nickolas; Hua Zhou; Donald J McMahon; Ralph Müller; Thomas Kohler; Alexander Zwahlen; Joan M Lappe; Polly Young; Robert R Recker; Elizabeth Shane
Journal:  J Clin Endocrinol Metab       Date:  2012-06-14       Impact factor: 5.958

Review 3.  Skeletal manifestations of treatment of breast cancer on premenopausal women.

Authors:  Loomee Doo; Charles L Shapiro
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 4.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

Review 5.  Premenopausal Osteoporosis.

Authors:  Adi Cohen
Journal:  Endocrinol Metab Clin North Am       Date:  2016-11-24       Impact factor: 4.741

6.  Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.

Authors:  Adi Cohen; Emily M Stein; Robert R Recker; Joan M Lappe; David W Dempster; Hua Zhou; Serge Cremers; Donald J McMahon; Thomas L Nickolas; Ralph Müller; Alexander Zwahlen; Polly Young; Julie Stubby; Elizabeth Shane
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

7.  Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement.

Authors:  Vaishali B Popat; Karim A Calis; Sophia N Kalantaridou; Vien H Vanderhoof; Deloris Koziol; James F Troendle; James C Reynolds; Lawrence M Nelson
Journal:  J Clin Endocrinol Metab       Date:  2014-06-06       Impact factor: 5.958

Review 8.  Bone disease in HIV infection: a practical review and recommendations for HIV care providers.

Authors:  Grace A McComsey; Pablo Tebas; Elizabeth Shane; Michael T Yin; E Turner Overton; Jeannie S Huang; Grace M Aldrovandi; Sandra W Cardoso; Jorge L Santana; Todd T Brown
Journal:  Clin Infect Dis       Date:  2010-10-15       Impact factor: 9.079

9.  Evaluation and management of the premenopausal woman with low BMD.

Authors:  Adi Cohen; Elizabeth Shane
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

10.  Z-score discordance and contributing factors in healthy premenopausal women with low bone mineral density: the Korean National Health and Nutrition Examination Survey 2008-9.

Authors:  Kyeong Hye Park; Jung Soo Lim; Kyoung Min Kim; Yumie Rhee; Sung-Kil Lim
Journal:  J Bone Miner Metab       Date:  2015-10-07       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.